Skip to main content

Table 2 ACQ score change from baseline to week 13 (ITT population)

From: A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma

Variable

Placebo

Combined MEDI-528

P Valueb

 

n

Mean (SD)

n

Mean (SD)

 

All subjectsa

82

−1.23 (0.95)

245

−1.22 (1.07)

0.86

Asthma typea

     

Atopic

70

−1.28 (0.97)

206

−1.19 (1.04)

0.55

Non-atopic

12

−0.94 (0.82)

39

−1.42 (1.18)

0.41

ICS usea

     

Medium dose

43

−1.21 (0.97)

117

−1.17 (1.02)

0.55

High dose

39

−1.26 (0.94)

128

−1.28 (1.11)

0.77

Eosinophil counta

     

≥ 0.3 × 103/μL

44

−1.39 (0.95)

120

−1.17 (1.01)

0.14

< 0.3 × 103/μL

38

−1.04 (0.92)

124

−1.26 (1.09)

0.22

All subjects without imputation

67

−1.30 (0.94)

208

−1.28 (1.10)

0.75

  1. Abbreviations: ACQ Asthma Control Questionnaire, ICS Inhaled corticosteroid.
  2. aMissing mean ACQ score at Week 13 was imputed using the last observation carried forward method.
  3. bP-values are calculated using an analysis of covariance with treatment and baseline value as covariates.